BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33430710)

  • 1.
    Loscocco GG; Rotunno G; Mannelli L; Mannelli F; Vergoni F; Guglielmelli P; Vannucchi AM
    Tumori; 2021 Dec; 107(6):NP28-NP32. PubMed ID: 33430710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.
    Chung SS; Kim E; Park JH; Chung YR; Lito P; Teruya-Feldstein J; Hu W; Beguelin W; Monette S; Duy C; Rampal R; Telis L; Patel M; Kim MK; Huberman K; Bouvier N; Berger MF; Melnick AM; Rosen N; Tallman MS; Park CY; Abdel-Wahab O
    Sci Transl Med; 2014 May; 6(238):238ra71. PubMed ID: 24871132
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Bibi A; Java S; Chaudhary S; Joshi S; Mascerhenas R; Rabade N; Tembhare P; Subramanian PG; Gujral S; Menon H; Khattry N; Sengar M; Bagal B; Jain H; Patkar N
    Indian J Pathol Microbiol; 2018; 61(4):532-536. PubMed ID: 30303143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological spectrum of hairy-cell leukemia: A single-center study with brief review of Indian literature.
    Gupta R; Yadav S; Mittal N; Rahman K; Sharma A; Gupta A; Nityan S
    J Cancer Res Ther; 2020; 16(1):120-126. PubMed ID: 32362621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutations in hairy-cell leukemia.
    Tiacci E; Trifonov V; Schiavoni G; Holmes A; Kern W; Martelli MP; Pucciarini A; Bigerna B; Pacini R; Wells VA; Sportoletti P; Pettirossi V; Mannucci R; Elliott O; Liso A; Ambrosetti A; Pulsoni A; Forconi F; Trentin L; Semenzato G; Inghirami G; Capponi M; Di Raimondo F; Patti C; Arcaini L; Musto P; Pileri S; Haferlach C; Schnittger S; Pizzolo G; Foà R; Farinelli L; Haferlach T; Pasqualucci L; Rabadan R; Falini B
    N Engl J Med; 2011 Jun; 364(24):2305-15. PubMed ID: 21663470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
    Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
    Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
    Buffet C; Hecale-Perlemoine K; Bricaire L; Dumont F; Baudry C; Tissier F; Bertherat J; Cochand-Priollet B; Raffin-Sanson ML; Cormier F; Groussin L
    PLoS One; 2017; 12(9):e0184861. PubMed ID: 28910386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
    Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
    Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report.
    Habberstad AH; Tran HTT; Randen U; Spetalen S; Dybedal I; Tjønnfjord GE; Dahm AEA
    J Med Case Rep; 2018 Apr; 12(1):105. PubMed ID: 29685167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
    An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
    Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
    Sadow PM; Heinrich MC; Corless CL; Fletcher JA; Nosé V
    Endocr Pathol; 2010 Jun; 21(2):73-9. PubMed ID: 20012784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
    Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
    Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome.
    Lakiotaki E; Levidou G; Angelopoulou MK; Adamopoulos C; Pangalis G; Rassidakis G; Vassilakopoulos T; Gainaru G; Flevari P; Sachanas S; Saetta AA; Sepsa A; Moschogiannis M; Kalpadakis C; Tsesmetzis N; Milionis V; Chatziandreou I; Thymara I; Panayiotidis P; Dimopoulou M; Plata E; Konstantopoulos K; Patsouris E; Piperi C; Korkolopoulou P
    Sci Rep; 2016 Feb; 6():21252. PubMed ID: 26893254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.
    Tiacci E; Schiavoni G; Martelli MP; Boveri E; Pacini R; Tabarrini A; Zibellini S; Santi A; Pettirossi V; Fortini E; Ascani S; Arcaini L; Inghirami G; Paulli M; Falini B
    Haematologica; 2013 Apr; 98(4):635-9. PubMed ID: 23349307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel BRAF and KRAS Mutations in Papillary Thyroid Carcinoma Arising in Struma Ovarii.
    Tan A; Stewart CJ; Garrett KL; Rye M; Cohen PA
    Endocr Pathol; 2015 Dec; 26(4):296-301. PubMed ID: 26362194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia.
    Ewalt M; Nandula S; Phillips A; Alobeid B; Murty VV; Mansukhani MM; Bhagat G
    Hematol Oncol; 2012 Dec; 30(4):190-3. PubMed ID: 22246856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
    Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
    Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies.
    Boyd EM; Bench AJ; van 't Veer MB; Wright P; Bloxham DM; Follows GA; Scott MA
    Br J Haematol; 2011 Dec; 155(5):609-12. PubMed ID: 21910720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.